Here are the 10-K annual reports from Traws Pharma, Inc. (TRAW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow TRAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRAW filings page.
Traws Pharma, Inc. filed Amendment No. 1 to its Form 10-K for the year ended December 31, 2025 to add Part III information on directors, executive officers, compensation, ownership and related-party matters because a proxy statement will not be filed within 120 days. The amendment does not update prior financial statements or other disclosures.
The filing details board composition, committee memberships, independence determinations, director and executive pay arrangements, equity awards, significant shareholders, related-party R&D and licensing agreements, and auditor fees, while affirming existing governance policies such as the code of conduct and insider trading policy.
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on antivirals for respiratory viral diseases, alongside legacy oncology assets. The company’s lead influenza candidate, tivoxavir marboxil (TXM), showed prolonged plasma exposure after a single dose and strong preclinical activity against H5N1 bird flu in multiple animal models.
Regulators have affirmed that clinical data are required for bird flu approval, and the U.S. IND for TXM is on clinical hold over toxicology concerns, which the company is working to address. Traws is prioritizing TXM as a once-monthly oral prophylactic for influenza and as a single-dose treatment for seasonal and H5N1 flu.
Ratutrelvir, an oral 3CL protease inhibitor for COVID-19, completed a 90‑patient Phase 2a study versus PAXLOVID, with reports of fewer adverse events, no viral rebound, and comparable symptom resolution. Oncology programs narazaciclib and rigosertib have completed or near-complete early studies and are now primarily positioned for partnering. Research and development expenses were $12.1 million in 2025 and $12.8 million in 2024.